Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Key Stats

• Today's Range: $10.55 to $11.05
• 50-Day Range: $6.70 to $10.98
• 52-Week Range: $5.51 to $11.73
• Volume: 33,206 shs
• Average Volume: 47,871 shs
• Market Capitalization: $207.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Buy

ACTU Stock Analysis - Frequently Asked Questions

How have ACTU shares performed this year?

Actuate Therapeutics' stock was trading at $7.96 at the beginning of 2025. Since then, ACTU shares have increased by 32.8% and is now trading at $10.57.
View the best growth stocks for 2025 here.

How were Actuate Therapeutics' earnings last quarter?

Actuate Therapeutics (NASDAQ:ACTU) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.06.

When did Actuate Therapeutics IPO?

Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Who are Actuate Therapeutics' major shareholders?

Top institutional investors of Actuate Therapeutics include Voss Capital LP (0.73%), Sigma Planning Corp (0.12%), Goldman Sachs Group Inc. (0.11%) and Sfmg LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis.
View institutional ownership trends.

How do I buy shares of Actuate Therapeutics?

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Actuate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACTU
• Previous Symbol: NASDAQ:ACTU
• CIK: 1652935
• Web: N/A
• Phone: (847) 986-4190
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.50
• High Stock Price Target: $21.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +89.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 19,620,000
• Free Float: N/A
• Market Cap: $212.48 million
• Optionable: N/A
• Beta: N/A